Silexion Therapeutics Corp has completed a significant preclinical study evaluating its RNA interference therapeutic candidate, SIL204, for various KRAS-driven cancers, including colorectal and ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

The investigational assay prospectively assesses KRAS status in patients with recurrent LGSOC to group patients into KRAS-mutation or KRAS-wild type cohorts for analysis in the primary and ...

Researchers at Novartis BioMedical Research in the US and Switzerland have identified a molecular target that may provide a ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

The review comes amid escalating costs linked to athlete training, infrastructure development, equipment procurement, and ...

“It does inhibit KRAS-G12C at a quicker rate [than a first-generation inhibitor] and most likely at a longer duration as well,” said Dr Herbert Loong Ho-fung, an associate professor at CUHK ...

Massachusetts-based PAQ Therapeutics, a biotech developing KRAS degraders for cancers lacking effective treatment options, ...